CL2021001433A1 - Terapia de combinación de radioinmunoconjugados con inhibidor del punto de control - Google Patents

Terapia de combinación de radioinmunoconjugados con inhibidor del punto de control

Info

Publication number
CL2021001433A1
CL2021001433A1 CL2021001433A CL2021001433A CL2021001433A1 CL 2021001433 A1 CL2021001433 A1 CL 2021001433A1 CL 2021001433 A CL2021001433 A CL 2021001433A CL 2021001433 A CL2021001433 A CL 2021001433A CL 2021001433 A1 CL2021001433 A1 CL 2021001433A1
Authority
CL
Chile
Prior art keywords
radioimmunoconjugate
combination therapy
checkpoint inhibitor
inhibitor combination
checkpoint
Prior art date
Application number
CL2021001433A
Other languages
English (en)
Spanish (es)
Inventor
Meiduo Hu
John Fitzmaurice Valliant
Julie Metcalf
Natalie Grinshtein
Eric Steven Burak
Original Assignee
Fusion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fusion Pharmaceuticals Inc filed Critical Fusion Pharmaceuticals Inc
Publication of CL2021001433A1 publication Critical patent/CL2021001433A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A61K51/1036—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A61K51/103—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against receptors for growth factors or receptors for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CL2021001433A 2018-12-03 2021-06-01 Terapia de combinación de radioinmunoconjugados con inhibidor del punto de control CL2021001433A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862774847P 2018-12-03 2018-12-03

Publications (1)

Publication Number Publication Date
CL2021001433A1 true CL2021001433A1 (es) 2021-12-03

Family

ID=70973593

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2021001433A CL2021001433A1 (es) 2018-12-03 2021-06-01 Terapia de combinación de radioinmunoconjugados con inhibidor del punto de control
CL2021001432A CL2021001432A1 (es) 2018-12-03 2021-06-01 Terapia de combinación de radioinmunoconjugados con inhibidores de daños y reparaciones del adn

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2021001432A CL2021001432A1 (es) 2018-12-03 2021-06-01 Terapia de combinación de radioinmunoconjugados con inhibidores de daños y reparaciones del adn

Country Status (18)

Country Link
US (5) US11446401B2 (cg-RX-API-DMAC7.html)
EP (2) EP3890790A4 (cg-RX-API-DMAC7.html)
JP (3) JP2022513700A (cg-RX-API-DMAC7.html)
KR (2) KR20210099073A (cg-RX-API-DMAC7.html)
CN (4) CN117482261A (cg-RX-API-DMAC7.html)
AU (2) AU2019394888A1 (cg-RX-API-DMAC7.html)
BR (2) BR112021010670A2 (cg-RX-API-DMAC7.html)
CA (2) CA3119917A1 (cg-RX-API-DMAC7.html)
CL (2) CL2021001433A1 (cg-RX-API-DMAC7.html)
EA (2) EA202191557A1 (cg-RX-API-DMAC7.html)
IL (2) IL283598A (cg-RX-API-DMAC7.html)
MA (2) MA54399A (cg-RX-API-DMAC7.html)
MX (2) MX2021006408A (cg-RX-API-DMAC7.html)
PE (2) PE20211961A1 (cg-RX-API-DMAC7.html)
PH (2) PH12021551237A1 (cg-RX-API-DMAC7.html)
SG (2) SG11202105112RA (cg-RX-API-DMAC7.html)
WO (2) WO2020115556A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202103429B (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3125197A1 (en) * 2019-01-04 2020-07-09 Actinium Pharmaceuticals, Inc. Methods for treating cancer using combinations of parp inhibitors and antibody radioconjugates
ES3075769T3 (en) 2019-05-10 2026-08-07 Janssen Biotech Inc Macrocyclic chelators and methods of use thereof
TW202131946A (zh) * 2020-01-10 2021-09-01 加拿大商融合製藥公司 持續性免疫療法
WO2021207086A1 (en) * 2020-04-06 2021-10-14 Fusion Pharmaceuticals Inc. Tem-1-targeted radioimmunoconjugates and uses thereof
CA3195512A1 (en) 2020-10-14 2022-04-21 Vahe Bedian Compositions and methods for treatment of thyroid eye disease
WO2022087023A1 (en) * 2020-10-19 2022-04-28 Baruch S. Blumberg Institute Methods and kits for diagnosing and treating cancers
WO2022169634A1 (en) * 2021-02-02 2022-08-11 Unm Rainforest Innovations Combination therapy for the treatment of cancer
JP2024521418A (ja) * 2021-06-11 2024-05-31 フュージョン ファーマシューティカルズ インコーポレイテッド 放射性免疫複合体とチェックポイント阻害剤併用療法
US11541134B1 (en) 2021-08-02 2023-01-03 Rayzebio, Inc. Stabilized compositions of radionuclides and uses thereof
JP2024531151A (ja) 2021-08-10 2024-08-29 ビリジアン セラピューティクス, インコーポレイテッド 甲状腺眼疾患の処置のための組成物、用量および方法
KR20240049818A (ko) * 2021-08-17 2024-04-17 테릭스 파마슈티컬스 (이노베이션스) 피티와이 엘티디 병용 방사선요법
US20250339571A1 (en) * 2021-08-27 2025-11-06 Actinium Pharmaceuticals, Inc. Radioimmunoconjugates targeting phosphatidylserine for use in the treatment of cancer
WO2023049985A1 (en) * 2021-09-29 2023-04-06 National Research Council Of Canada Egfrviii-targeted compounds and uses thereof
AU2022379928A1 (en) * 2021-11-02 2024-05-09 Fusion Pharmaceuticals Inc. Methods of treating cancer
JP2025503215A (ja) * 2022-01-28 2025-01-30 フュージョン ファーマシューティカルズ インコーポレイテッド Ntsr1標的化放射性医薬品およびdna損傷応答阻害剤併用療法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5053503A (en) * 1989-02-17 1991-10-01 Centocor Chelating agents
JPH07503124A (ja) 1991-06-14 1995-04-06 ゾーマ・コーポレーション 微生物によって生産される抗体断片とそれらの複合体
JP3876002B2 (ja) 1997-04-14 2007-01-31 ミクロメート・アクチエンゲゼルシャフト 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用
US7736651B1 (en) * 2000-11-24 2010-06-15 Sloan-Kettering Institute For Cancer Research Alpha emitting constructs and uses thereof
CA2593212A1 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Cripto binding molecules
JP2009532027A (ja) * 2006-03-28 2009-09-10 バイオジェン・アイデック・エムエイ・インコーポレイテッド 抗igf−1r抗体およびその使用
US9556272B2 (en) * 2009-11-11 2017-01-31 The Trustees Of The University Of Pennsylvania Anti-TEM1 antibodies and uses thereof
IN2012DN03354A (cg-RX-API-DMAC7.html) 2009-12-02 2015-10-23 Immunomedics Inc
GB201120779D0 (en) 2011-12-02 2012-01-11 Immodulon Therapeutics Ltd Cancer therapy
GB201403875D0 (en) * 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
KR20190072663A (ko) * 2014-04-25 2019-06-25 리나트 뉴로사이언스 코프. 약물이 고도로 로딩된 항체-약물 접합체
US10092645B2 (en) 2014-06-17 2018-10-09 Medimmune Limited Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy
EP3280439A1 (en) * 2015-04-07 2018-02-14 INSERM - Institut National de la Santé et de la Recherche Médicale Anti-pd-l1 immunotoxin for use in therapy
US11149087B2 (en) * 2015-04-20 2021-10-19 Etubics Corporation Methods and compositions for combination immunotherapy
AU2016252038B2 (en) * 2015-04-20 2021-08-12 Effector Therapeutics, Inc. Inhibitors of immune checkpoint modulators for use in treating cancer and infections
US20180169230A1 (en) * 2015-05-29 2018-06-21 Merrimack Pharmaceuticals, Inc. Combination cancer therapies
JP7012645B2 (ja) * 2016-01-11 2022-01-28 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー キメラタンパク質および免疫治療の方法
EP3202788A1 (en) 2016-02-05 2017-08-09 MediaPharma S.r.l. Endosialin-binding antibody
TWI822521B (zh) * 2016-05-13 2023-11-11 美商再生元醫藥公司 藉由投予pd-1抑制劑治療皮膚癌之方法
US11633506B2 (en) * 2016-07-18 2023-04-25 Wisconsin Alumni Research Foundation Using targeted radiotherapy (TRT) to drive anti-tumor immune response to immunotherapies
WO2018031507A1 (en) 2016-08-09 2018-02-15 Angimmune, Llc Treatment of cancer using a combination of immunomodulation and check point inhibitors
ES3071660T3 (en) * 2016-08-24 2026-06-24 Scinopharm Taiwan Ltd Processes for preparing olaparib
CA3035262A1 (en) * 2016-09-16 2018-03-22 Tina Christine Lavranos Antibody and checkpoint inhibitor combination therapy
JPWO2018110515A1 (ja) * 2016-12-12 2019-10-24 第一三共株式会社 抗体−薬物コンジュゲートと免疫チェックポイント阻害剤の組み合わせ
WO2018153975A1 (en) * 2017-02-24 2018-08-30 Bayer As Combination therapy comprising a radiopharmaceutical and a dna-repair inhibitor
WO2018204872A2 (en) * 2017-05-05 2018-11-08 Fusion Pharmaceuticals Inc. Igf-1r monoclonal antibodies and uses thereof
AU2018261888B2 (en) * 2017-05-05 2022-06-30 Centre For Probe Development And Commercialization Pharmacokinetic enhancements of bifunctional chelates and uses thereof
US10093741B1 (en) * 2017-05-05 2018-10-09 Fusion Pharmaceuticals Inc. IGF-1R monoclonal antibodies and uses thereof
EP3681541A4 (en) * 2017-09-13 2021-05-26 Radimmune Therapeutics, Inc. MELANINE ANTIBODIES AND USES THEREOF
CN111372613A (zh) * 2017-11-22 2020-07-03 诺帝克纳诺维科特公司 放射免疫缀合物与其他药物联合治疗非霍奇金淋巴瘤
WO2020169537A1 (en) * 2019-02-21 2020-08-27 Bayer Aktiengesellschaft Combination of pd-1/pd-l1 inhibitors and targeted thorium conjugates

Also Published As

Publication number Publication date
US20210290789A1 (en) 2021-09-23
MX2021006408A (es) 2021-10-22
MA54401A (fr) 2021-10-13
BR112021010799A2 (pt) 2021-08-24
US20230270895A1 (en) 2023-08-31
EP3890789A1 (en) 2021-10-13
MA54399A (fr) 2021-10-13
PE20211961A1 (es) 2021-10-04
KR20210099073A (ko) 2021-08-11
IL283613A (en) 2021-07-29
JP2022513700A (ja) 2022-02-09
CN113164632A (zh) 2021-07-23
EA202191557A1 (ru) 2021-10-14
PH12021551237A1 (en) 2021-11-03
BR112021010670A2 (pt) 2021-08-24
SG11202105112RA (en) 2021-06-29
MX2021006407A (es) 2021-10-22
CN117482261A (zh) 2024-02-02
US20220088230A1 (en) 2022-03-24
AU2019393257A1 (en) 2021-06-03
PH12021551282A1 (en) 2021-12-06
ZA202103429B (en) 2023-11-29
CN120393061A (zh) 2025-08-01
CL2021001432A1 (es) 2021-12-17
CA3119915A1 (en) 2020-06-11
EP3890790A4 (en) 2022-12-14
KR20210099074A (ko) 2021-08-11
EP3890790A1 (en) 2021-10-13
SG11202105192WA (en) 2021-06-29
US11446401B2 (en) 2022-09-20
IL283598A (en) 2021-07-29
CA3119917A1 (en) 2020-06-11
EP3890789A4 (en) 2022-12-14
WO2020115548A1 (en) 2020-06-11
JP2025013486A (ja) 2025-01-24
WO2020115556A1 (en) 2020-06-11
AU2019394888A1 (en) 2021-06-10
EA202191556A1 (ru) 2021-10-14
JP2022511471A (ja) 2022-01-31
PE20211286A1 (es) 2021-07-19
CN113474014A (zh) 2021-10-01
US20220088231A1 (en) 2022-03-24
US20210290788A1 (en) 2021-09-23

Similar Documents

Publication Publication Date Title
MX2021006407A (es) Terapia de combinacion de radioinmunoconjugados con inhibidor del punto de control.
IL282727A (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
CL2019001874A1 (es) Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos.
MX2019011657A (es) Combinacion de un anticuerpo anti ligando 1 de muerte programada (pd-l1) e inhibidor de proteina cinasa dependiente de acido desoxirribonucleico (dna-pk) para tratamiento de cancer.
MX2020013728A (es) Combinacion de inmunoterapias con inhibidores de mdm2.
EP4331556C0 (en) DEVICES AND SYSTEMS FOR ADMINISTERING POLYTHERAPIES
MX387283B (es) Tratamiento del cancer con tg02.
JOP20200220A1 (ar) أجهزة لحقن أدوية وطرق استخدامها
BR112018013995A2 (pt) terapia de combinação de vírus oncolítico e inibidor de ponto de verificação
MX373045B (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
MX377351B (es) Metodos para el tratamiento de cancer utilizando inhibidores b-raf e inhibidores de punto de control inmunologico
BR112019005908A2 (pt) uso de combinação de anticorpo anti-pd-1 e inibidor de vegfr na preparação de fármaco para tratamento de cânceres
MX2018010709A (es) Terapia del cancer con un virus oncolitico combinado con un inhibidor de punto de control.
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
BR112019003533A2 (pt) terapia de combinação com inibidores de glutaminase
BR112019003722A2 (pt) terapias de combinação para o tratamento de carcinoma hepatocelular
BR112019019261A2 (pt) Terapias de combinação para o tratamento de câncer de mama
AR126128A1 (es) Terapia de combinación de radioinmunoconjugados e inhibidores de puntos de control
MX2024009313A (es) Radiofarmacos dirigidos al psma e inhibidor de punto de control.
MX2020007375A (es) Terapias de combinacion para el tratamiento de carcinoma hepatocelular.
MX2024009317A (es) Radiofarmacos dirigidos a ntsr1 y terapia de combinacion de inhibidores punto de control.
MX2020011912A (es) Terapia de combinacion para el tratamiento del virus de la hepatitis c (vhc).
MX2020004731A (es) Terapias de combinacion de inhibidor ezh2.
HK40062172A (en) Radioimmunoconjugates and checkpoint inhibitor combination therapy
AR114935A1 (es) Terapias de combinación